Ratings Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Real-time Estimate Cboe BZX Other stock markets 10:51:35 2024-04-29 am EDT			5-day change	1st Jan Change
5.47 ^USD	+1.11%		+10.93%	+12.07%

Apr. 24	Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	MT
Apr. 24	Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CAPRICOR THERAPEUTICS, INC.	+12.07%	170M	-
VERTEX PHARMACEUTICALS INCORPORATED	-2.37%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+1.85%	95.28B	B+
ARGENX SE	+2.18%	22.15B	B
BIONTECH SE	-15.79%	21.02B	B+
GENMAB A/S	-8.26%	18.15B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.73B	A-
BEIGENE, LTD.	-13.67%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+3.96%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+34.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes